Poolbeg Pharma Past Earnings Performance

Past criteria checks 0/6

Poolbeg Pharma's earnings have been declining at an average annual rate of -25.6%, while the Pharmaceuticals industry saw earnings declining at 1.7% annually.

Key information

-25.6%

Earnings growth rate

-1.9%

EPS growth rate

Pharmaceuticals Industry Growth14.1%
Revenue growth raten/a
Return on equity-29.5%
Net Marginn/a
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Feb 16
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Oct 05
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Jun 01
We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12
Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Revenue & Expenses Breakdown
Beta

How Poolbeg Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

AIM:POLB Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 230-532
31 Mar 230-532
31 Dec 220-532

Quality Earnings: POLB is currently unprofitable.

Growing Profit Margin: POLB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if POLB's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare POLB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: POLB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.7%).


Return on Equity

High ROE: POLB has a negative Return on Equity (-29.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.